A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer

Study identifier:D9570C00001

ClinicalTrials.gov identifier:NCT04931654

EudraCT identifier:2021-000036-57

CTIS identifier:2022-502774-17-00

Recruiting

Official Title

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors.

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD7789

Sex

All

Estimated Enrollment

232

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 28 Sept 2021
Estimated Primary Completion Date: 25 Aug 2026
Estimated Study Completion Date: 25 Aug 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria